WO2012173383A3 - 크립토탄시논을 유효성분으로 함유하는 피부 외용제 조성물 - Google Patents

크립토탄시논을 유효성분으로 함유하는 피부 외용제 조성물 Download PDF

Info

Publication number
WO2012173383A3
WO2012173383A3 PCT/KR2012/004647 KR2012004647W WO2012173383A3 WO 2012173383 A3 WO2012173383 A3 WO 2012173383A3 KR 2012004647 W KR2012004647 W KR 2012004647W WO 2012173383 A3 WO2012173383 A3 WO 2012173383A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin
active ingredient
external use
use containing
skin composition
Prior art date
Application number
PCT/KR2012/004647
Other languages
English (en)
French (fr)
Other versions
WO2012173383A2 (ko
Inventor
이옥찬
염명훈
조가영
이진영
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Publication of WO2012173383A2 publication Critical patent/WO2012173383A2/ko
Publication of WO2012173383A3 publication Critical patent/WO2012173383A3/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 크립토탄시논(Cryptotanshinone), 그의 이성질체, 그의 전구체, 그의 염, 그의 수화물 또는 그의 용매화물을 유효성분으로 함유하는 피부 외용제 조성물을 제공한다. 본 발명의 조성물은 피부 노화 억제, 피부 주름 개선, 피부 미백, 피부 보습, 아토피 개선, 피부 혈색 개선 및 피부 투명도 개선 효과가 있다.
PCT/KR2012/004647 2011-06-17 2012-06-13 크립토탄시논을 유효성분으로 함유하는 피부 외용제 조성물 WO2012173383A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0058903 2011-06-17
KR20110058903A KR101481208B1 (ko) 2011-06-17 2011-06-17 크립토탄시논을 유효성분으로 함유하는 피부 외용제 조성물

Publications (2)

Publication Number Publication Date
WO2012173383A2 WO2012173383A2 (ko) 2012-12-20
WO2012173383A3 true WO2012173383A3 (ko) 2013-03-14

Family

ID=47357593

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/004647 WO2012173383A2 (ko) 2011-06-17 2012-06-13 크립토탄시논을 유효성분으로 함유하는 피부 외용제 조성물

Country Status (2)

Country Link
KR (1) KR101481208B1 (ko)
WO (1) WO2012173383A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102001048B1 (ko) * 2013-08-14 2019-07-17 주식회사 엘지생활건강 피부 재생, 주름개선, 항산화 및 피부 미백용 조성물
CN104473784B (zh) * 2014-11-24 2017-08-22 广州神采化妆品有限公司 一种出油按摩膏及其制备方法
CN111420023B (zh) * 2020-04-30 2024-03-15 广州市红十字会医院(暨南大学医学院附属广州红十字会医院) 含i型胶原和透明质酸的复合物及制备和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050071355A (ko) * 2003-12-30 2005-07-07 주식회사 케이티앤지 대사활성을 촉진시키는 탄시논 유도체를 유효성분으로함유하는 비만 및 대사증후군 치료제
US20060045896A1 (en) * 2004-08-31 2006-03-02 Tracie Martyn International, Llc Topical compositions comprising benfotiamine and pyridoxamine
KR100861186B1 (ko) * 2001-03-26 2008-09-30 주식회사 엘지생활건강 크립토탄시논을 함유하는 여드름 예방 및 치료용 화장료
WO2009050451A1 (en) * 2007-10-15 2009-04-23 Botanic Century (Beijing) Co. Ltd Antibacterial composition comprising salvia extracts

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100861186B1 (ko) * 2001-03-26 2008-09-30 주식회사 엘지생활건강 크립토탄시논을 함유하는 여드름 예방 및 치료용 화장료
KR20050071355A (ko) * 2003-12-30 2005-07-07 주식회사 케이티앤지 대사활성을 촉진시키는 탄시논 유도체를 유효성분으로함유하는 비만 및 대사증후군 치료제
US20060045896A1 (en) * 2004-08-31 2006-03-02 Tracie Martyn International, Llc Topical compositions comprising benfotiamine and pyridoxamine
WO2009050451A1 (en) * 2007-10-15 2009-04-23 Botanic Century (Beijing) Co. Ltd Antibacterial composition comprising salvia extracts

Also Published As

Publication number Publication date
KR101481208B1 (ko) 2015-01-12
KR20120139223A (ko) 2012-12-27
WO2012173383A2 (ko) 2012-12-20

Similar Documents

Publication Publication Date Title
EP3199036A4 (en) Composition, containing tyndallized lactobacillus dead cells as active ingredient, for skin moisturizing or wrinkle improvement
WO2013158851A3 (en) Improving skin appearance with increase in skin chroma
EP3060041A4 (en) Prostacyclin compounds, compositions and methods of use thereof
EP2827869A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO
HK1186965A1 (zh) 用於美白和改善皮膚彈性的化妝品組合物
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
HK1178465A1 (en) Composition for improving condition of skin
EP2654745A4 (en) COMPOSITION FOR TREATING SKIN CONDITIONS OF THE SKIN
WO2013098416A3 (fr) Composes anti-douleur
EP3354254A4 (en) SKIN-SHELLING COMPOSITION WITH BETA-MANGOSTINE AS AN ACTIVE SUBSTANCE
WO2013034855A3 (fr) Association de carraghénane et de c-glycoside et leurs utilisations
WO2013002518A3 (ko) 화장료 조성물을 포함하는 피부 미용 키트 및 도포방법
WO2012076109A3 (de) 2-pyrone
EP2994134A4 (en) Methods of administering dantrolene for the acute treatment of cardiac arrhythmias
MX2014009750A (es) Composiciones antifungicas para el tratamiento de piel y uñas.
EP3052078A4 (en) Methods and compositions for improving the appearance of skin
HK1185290A1 (zh) 改善面部毛孔的外觀的組合物和方法
WO2012173382A3 (ko) 탄시논ⅱa를 유효성분으로 함유하는 피부 외용제 조성물
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
WO2012128971A3 (en) Topical acyl glutathione formulations
WO2012104332A3 (de) Desodorierender hautfilm
WO2013012197A3 (ko) 허니부쉬 추출물 또는 이의 발효액을 유효성분으로 함유하는 피부 주름 예방 또는 개선용 조성물
EP3061448A4 (en) Composition containing eugenol as active ingredient for preventing or treating atopic dermatitis
EP2533752B8 (de) Zubereitungen zur stabilisierung / aufbau der textur lebender gewebe wie haut, und deren anwendungen
WO2012173383A3 (ko) 크립토탄시논을 유효성분으로 함유하는 피부 외용제 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12800469

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 07/04/2014)

122 Ep: pct application non-entry in european phase

Ref document number: 12800469

Country of ref document: EP

Kind code of ref document: A2